Clinical Study

Lisdexamfetamine In Binge Eating Disorder (Bed): Fmri Effects

Posted Date: May 9, 2017

  • Investigator: Susan Lynn Mcelroy
  • Specialties:
  • Type of Study: Drug

The purpose of this research study is to gather information about the effects of Lisdexamfetamine treatment on brain function in Binge Eating Disorder (BED) patients undergoing 12 weeks of open-label treatment. To do so, we will use magnetic resonance imaging (MRI) to examine brain structure and function. Lisdexamfetamine is the only medication approved by United States Food and Drug Administration (FDA) for BED.By completing this study we hope to better understand who benefits from treatment and why they do or do not respond to medications. With this information, we hope to be able to improve treatment and outcome in people with BED.

Criteria:

You Are Being Asked To Take Part In This Research Study Because You Are A Woman, 18 To 55 Years Of Age, Inclusive, You Have Been Diagnosed With Bed, And You Are Currently Seeking Treatment For Bed At Lindner Center Of Hope. Bed Is The Most Common Eating Disorder And Is Associated With Psychopathology (Mood, Anxiety, And Substance Use Disorders), Obesity, Reduced Quality Of Life, And Disability. You Do Not Need To Participate In This Research Study To Be Treated For Bed.

Keywords:

Approved Medication For Binge Eating, Binge, Binge Eating, Lisdexamfetamine, Vyvanse

For More Information:

Anna
Guerdjikova
anna.guerdjikova@lindnercenter.org